Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hwang, In Gyu | - |
dc.contributor.author | Kang, Jung Hun | - |
dc.contributor.author | Oh, Sung Yong | - |
dc.contributor.author | Lee, Suee | - |
dc.contributor.author | Kim, Sung-Hyun | - |
dc.contributor.author | Song, Ki-Hoon | - |
dc.contributor.author | Son, Choonhee | - |
dc.contributor.author | Park, Min Jae | - |
dc.contributor.author | Kang, Myung Hee | - |
dc.contributor.author | Kim, Hoon Gu | - |
dc.contributor.author | Lee, Jeeyun | - |
dc.contributor.author | Park, Young Suk | - |
dc.contributor.author | Sun, Jong Mu | - |
dc.contributor.author | Kim, Hyun Jung | - |
dc.contributor.author | Kim, Chan Kyu | - |
dc.contributor.author | Yi, Seong Yoon | - |
dc.contributor.author | Jang, Joung-Soon | - |
dc.contributor.author | Park, Keunchil | - |
dc.contributor.author | Kim, Hyo-Jin | - |
dc.date.available | 2019-03-08T13:56:14Z | - |
dc.date.issued | 2016-01 | - |
dc.identifier.issn | 0941-4355 | - |
dc.identifier.issn | 1433-7339 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/7402 | - |
dc.description.abstract | The efficacy of erlotinib, the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has been demonstrated in patients with non-small cell lung cancer (NSCLC) and pancreatic cancer (PC). In the present study, we evaluated the effect of epidermal growth factor (EGF) ointment on erlotinib-related skin effects (ERSEs). This was an open-label, non-comparative, multicenter, phase II trial. The patients included those diagnosed with NSCLC or PC who were treated with erlotinib. The effectiveness of the ointment was defined as follows: (1) grade 2, 3, or 4 ERSEs downgraded to a parts per thousand currency signgrade 1 or (2) grade 3 or 4 ERSEs downgraded to grade 2 and persisted for at least 2 weeks. Fifty-two patients from seven institutes in Korea were enrolled with informed consent. The final assessment included 46 patients (30 males, 16 females). According to the definition of effectiveness, the EGF ointment was effective in 36 (69.2 %) intention to treat patients. There were no statistically significant differences in the effectiveness of the EGF ointment by gender (p = 0.465), age (p = 0.547), tumor type (p = 0.085), erlotinib dosage (p = 0.117), and number of prior chemotherapy sessions (p = 0.547). The grading for the average National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) rating of rash/acne and itching improved from 2.02 +/- A 0.83 to 1.13 +/- A 0.89 and 1.52 +/- A 0.84 to 0.67 +/- A 0.90, respectively (p < 0.001). The most common reason for discontinuing the study was progression of cancer (37 %). Based on the results, the EGF ointment is effective for ERSEs, regardless of gender, age, type of tumor, and dosage of erlotinib. The EGF ointment evenly improved all kinds of symptoms of ERSEs. ClinicalTrials.gov identifier: NCT01593995. | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | SPRINGER | - |
dc.title | Phase II trial of epidermal growth factor ointment for patients with Erlotinib-related skin effects | - |
dc.type | Article | - |
dc.identifier.doi | 10.1007/s00520-015-2783-9 | - |
dc.identifier.bibliographicCitation | SUPPORTIVE CARE IN CANCER, v.24, no.1, pp 301 - 309 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.wosid | 000365817800038 | - |
dc.identifier.scopusid | 2-s2.0-84949098763 | - |
dc.citation.endPage | 309 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 301 | - |
dc.citation.title | SUPPORTIVE CARE IN CANCER | - |
dc.citation.volume | 24 | - |
dc.type.docType | Article | - |
dc.publisher.location | 미국 | - |
dc.subject.keywordAuthor | Erlotinib | - |
dc.subject.keywordAuthor | Skin reaction | - |
dc.subject.keywordAuthor | Epidermal growth factor | - |
dc.subject.keywordAuthor | Ointment | - |
dc.subject.keywordPlus | CELL LUNG-CANCER | - |
dc.subject.keywordPlus | METASTATIC COLORECTAL-CANCER | - |
dc.subject.keywordPlus | INDUCED ACNEIFORM ERUPTION | - |
dc.subject.keywordPlus | FACTOR RECEPTOR EGFR | - |
dc.subject.keywordPlus | QUALITY-OF-LIFE | - |
dc.subject.keywordPlus | CLINICAL-TRIALS | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | DERMATOLOGICAL TOXICITIES | - |
dc.subject.keywordPlus | CUTANEOUS TOXICITIES | - |
dc.subject.keywordPlus | KINASE INHIBITORS | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Health Care Sciences & Services | - |
dc.relation.journalResearchArea | Rehabilitation | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Health Care Sciences & Services | - |
dc.relation.journalWebOfScienceCategory | Rehabilitation | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.